NEW YORK (GenomeWeb News) – Pressure BioSciences has filed with US regulators for a direct offering of a maximum of $5 million of its Series F preferred stock.

In an amended preliminary prospectus filed with the US Securities and Exchange Commission on Friday, Pressure Bio said it plans to offer 5,000 shares of its Series F preferred stock at $1,000 per share. The stock is being offered directly to one or more accredited investors.

Moody Capital Solutions is acting as placement agent on the offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.